SA
Sign upLog In
NRXP

NRx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for central nervous system disorders, particularly its lead candidate, NRX-101, aimed at treating severe depression and PTSD. The company operates primarily in the United States and leverages its proprietary formulations to differentiate itself in a competitive market.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and clinical trials, with no current revenue, leading to significant operating losses.

Business Overview

01Product sales from NRX-101 (0% of total, as product is not yet commercialized)
02Potential licensing agreements (0% of total, speculative)

NRx Pharmaceuticals aims to monetize its proprietary drug candidates through eventual commercialization and partnerships with larger pharmaceutical companies. The company has a competitive advantage through its unique formulation of NRX-101, which combines two established drugs to target treatment-resistant conditions, potentially allowing for higher efficacy and better patient outcomes.

What Moves the Stock

Clinical trial results for NRX-101, particularly Phase 3 outcomes

Regulatory approvals from the FDA or other health authorities

Partnership announcements with larger pharmaceutical firms

Market sentiment regarding mental health treatment advancements

Watch on Earnings
Clinical trial progress updatesCash burn ratePartnership or licensing deal announcements

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption in drug development methodologies

Emergence of alternative therapies for depression and PTSD

Potential for larger pharmaceutical companies to dominate the market with similar products

High cash burn rate leading to potential liquidity issues

Dependence on future financing rounds to sustain operations

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The demand for healthcare products can be somewhat insulated from economic downturns, but funding for biotech ventures may tighten during recessions.

Interest Rates

Higher interest rates could increase the cost of capital for NRx Pharmaceuticals, affecting its ability to finance clinical trials and operations, which are heavily reliant on external funding.

Credit

minimal - The company has a negative debt/equity ratio, indicating minimal reliance on debt financing.

Live Conditions
Russell 2000 FuturesDow Jones FuturesS&P 500 Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

high - The stock is likely to experience significant volatility due to binary events such as clinical trial results.

Key Metrics to Watch
Clinical trial enrollment rates for NRX-101
Cash runway (months until funding is needed)
Regulatory feedback from the FDA
Market trends in mental health therapies

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.